X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs IPCA LABS - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS IPCA LABS NOVARTIS/
IPCA LABS
 
P/E (TTM) x 385.6 29.2 1,320.7% View Chart
P/BV x 33.9 3.7 913.5% View Chart
Dividend Yield % 1.3 0.1 1,066.4%  

Financials

 NOVARTIS   IPCA LABS
EQUITY SHARE DATA
    NOVARTIS
Mar-18
IPCA LABS
Mar-18
NOVARTIS/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs758695 109.0%   
Low Rs579400 144.8%   
Sales per share (Unadj.) Rs228.4260.2 87.8%  
Earnings per share (Unadj.) Rs31.719.0 167.3%  
Cash flow per share (Unadj.) Rs32.833.1 99.1%  
Dividends per share (Unadj.) Rs10.001.00 1,000.0%  
Dividend yield (eoy) %1.50.2 819.3%  
Book value per share (Unadj.) Rs297.1213.0 139.5%  
Shares outstanding (eoy) m24.69126.20 19.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.92.1 139.1%   
Avg P/E ratio x21.128.9 73.0%  
P/CF ratio (eoy) x20.416.6 123.1%  
Price / Book Value ratio x2.22.6 87.5%  
Dividend payout %31.55.3 597.8%   
Avg Mkt Cap Rs m16,50569,120 23.9%   
No. of employees `0000.713.3 5.0%   
Total wages/salary Rs m1,4457,359 19.6%   
Avg. sales/employee Rs Th8,441.32,477.4 340.7%   
Avg. wages/employee Rs Th2,163.6555.2 389.7%   
Avg. net profit/employee Rs Th1,173.1180.6 649.4%   
INCOME DATA
Net Sales Rs m5,63932,836 17.2%  
Other income Rs m1,718418 411.1%   
Total revenues Rs m7,35733,254 22.1%   
Gross profit Rs m-634,505 -1.4%  
Depreciation Rs m251,777 1.4%   
Interest Rs m55240 23.0%   
Profit before tax Rs m1,5752,905 54.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m792511 154.9%   
Profit after tax Rs m7842,394 32.7%  
Gross profit margin %-1.113.7 -8.1%  
Effective tax rate %50.317.6 285.7%   
Net profit margin %13.97.3 190.6%  
BALANCE SHEET DATA
Current assets Rs m9,52219,455 48.9%   
Current liabilities Rs m3,29610,076 32.7%   
Net working cap to sales %110.428.6 386.5%  
Current ratio x2.91.9 149.6%  
Inventory Days Days3798 37.4%  
Debtors Days Days2867 42.5%  
Net fixed assets Rs m4620,260 0.2%   
Share capital Rs m123252 48.9%   
"Free" reserves Rs m7,21326,633 27.1%   
Net worth Rs m7,33626,886 27.3%   
Long term debt Rs m02,340 0.0%   
Total assets Rs m11,10541,173 27.0%  
Interest coverage x29.513.1 225.2%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.50.8 63.7%   
Return on assets %7.66.4 118.1%  
Return on equity %10.78.9 119.9%  
Return on capital %22.210.8 206.5%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m6115,642 0.4%   
Fx outflow Rs m3,6304,884 74.3%   
Net fx Rs m-3,57010,759 -33.2%   
CASH FLOW
From Operations Rs m1,6103,411 47.2%  
From Investments Rs m687-1,354 -50.7%  
From Financial Activity Rs m-2,677-1,304 205.2%  
Net Cashflow Rs m-380753 -50.4%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 11.4 17.5%  
FIIs % 1.6 25.3 6.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 17.4 123.6%  
Shareholders   41,647 36,892 112.9%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   BIOCON LTD  CADILA HEALTHCARE  SUVEN LIFE  PANACEA BIOTECH  WOCKHARDT LTD.  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Dec 14, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS